How to buy Bristol-Myers Squibb (BMY) stock from India

Yes, an Indian resident can buy Bristol-Myers Squibb — legally, in US dollars, under the RBI's Liberalised Remittance Scheme (LRS). BMY trades on NYSE. It pays a quarterly dividend (~5% yield at current prices). BMY is navigating a dual LOE cliff — Revlimid generics since 2022 and Eliquis LOE in 2026 — while building growth through Opdivo combinations, Breyanzi (CAR-T cell therapy), Reblozyl (anemia), and Camzyos (hypertrophic cardiomyopathy). The high yield reflects both the income and the uncertainty around the LOE transition.

The 30-second version

• Legal and simple. Buy BMY via Vested, INDmoney, or Interactive Brokers India.
• Quarterly dividend (~5% yield). File Form W-8BEN for 15% DTAA withholding; claim FTC via Form 44.
• India tax on gains: hold more than 24 months → 12.5% LTCG (Section 112); shorter hold → slab rate.
• Estate-tax trap: above $60,000 US-situs → up to 40% US estate tax; no treaty relief.
• The position: BMY is the most compressed large-cap pharma by valuation — trading below 10× earnings as the market discounts Eliquis LOE. If the new product portfolio (Breyanzi, Camzyos, Reblozyl) achieves management's peak revenue guidance, the stock re-rates. The 5% dividend is the income floor while you wait.

Quick facts

Ticker / exchange	BMY / NYSE
Dividend	~$0.62/quarter (~5% annual yield)
India tax on gains	12.5% LTCG after 24 months; else slab (Section 112)
Dividend tax	15% US WHT (DTAA) + Indian slab; FTC via Form 44
Estate-tax risk	US-situs above $60k → up to 40%
Annual compliance	Schedule FA every year you hold

What Bristol-Myers Squibb actually is

Opdivo (nivolumab): PD-1 checkpoint inhibitor — the second major drug in the class after Keytruda, approved in melanoma, NSCLC, bladder, RCC, HCC, and combinations with Yervoy (ipilimumab). Running at ~$10B+ annual revenue; key growth driver in combination regimens and first-line approvals.

Eliquis (apixaban): Co-promoted with Pfizer — the world's leading oral anticoagulant. US LOE in 2026 is the headline risk for 2026–2027.

Breyanzi (lisocabtagene maraleucel): CD19-directed CAR-T for large B-cell lymphoma. Premium-priced cell therapy ($500K+ per treatment) growing in both lymphoma and CLL indications. CAR-T is the premium oncology modality with limited biosimilar risk.

Camzyos (mavacamten): First-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy (HCM). Approved 2022; growing with expanded REMS programme.

Reblozyl (luspatercept): TGF-β inhibitor for anemia in myelodysplastic syndromes and beta-thalassemia. Growing in first-line lower-risk MDS.

Tax and compliance

Capital gains: 12.5% LTCG after 24 months; slab for shorter holds. Dividend: 15% US WHT (W-8BEN) + Indian slab; FTC via Form 44. Schedule FA mandatory.

Full rules: how US stocks are taxed in India. Estate-tax: guide.

BMY vs MRK vs ABBV vs PFE

If you want…	Best route
Deepest value LOE recovery, Breyanzi CAR-T	BMY
Keytruda SC migration + growth	MRK
Humira replacement (Skyrizi/Rinvoq)	ABBV
High yield post-COVID reset, Seagen ADCs	PFE
Full pharma picture	Pharma & GLP-1 stocks guide